CPhI Aims for Russia
In 20011, the organisers of CPhI, UMB Live, announced their intention to explore the US via the launch of ICSE USA. This year, the organisers are once again setting their sights on new territory, this time in Russia.
In 2011, the organisers of CPhI, UMB Live, announced their intention to explore the US via the launch of ICSE USA. This year, the organisers are once again setting their sights on new territory, this time in Russia.
CPhI Russia is due to take place in Russia’s St Petersburg at the Manege Central Exhibition Hall on 10–11 April 2013, alongside the IPhEB event, which is a key event in Russia for the pharmaceutical, biotechnological and medical industry. In a statement, UBM Live said that it had actively sought a partnership with RESTEC, the organiser of IPhEB, to facilitate access to the Russian market.
“The Russian pharmaceutical market is set for tremendous growth: this year we already have seen leading pharmaceutical companies, such as Novartis and AstraZeneca, opening manufacturing sites and R&D centres in the St. Petersburg region and other parts of Russia. We believe our industry leading face-to-face events and digital products can play a critical role in accelerating that growth and driving innovation in the Russian pharmaceutical market," Andrew Pert, brand director for CPhI Russia, said in a statement.
According to a survey conducted by UBM Live of visitors to CPhI Worldwide 2011, held in Frankfurt, 42% of attendees were already active in the Russian pharmaceutical market. More than one third also had plans to enter the market during the next two years.
Russia is currently the eleventh largest pharmaceutical market in the world and is projected to reach a value of $26.7 billion by the end of 2013.
You can find out more about CPhI Russia and register your interest here.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.
